NOVAVAX, INC

Lobbying for NOVAVAX, INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Maryland · House · Senate · $170,000.00 expenses · posted Apr 28, 2025

Lobbying activity 1

Health Issues

Issues related to COVID-19 vaccines Reauthorization of Pandemic and All-Hazards Preparedness Act General discussions related to vaccine injury compensation programs and vaccine strain selection timelines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.